GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ekso Bionics Holdings Inc (NAS:EKSO) » Definitions » Piotroski F-Score
中文

Ekso Bionics Holdings (Ekso Bionics Holdings) Piotroski F-Score

: 3 (As of Today)
View and export this data going back to 2013. Start your Free Trial

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Ekso Bionics Holdings has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Ekso Bionics Holdings's Piotroski F-Score or its related term are showing as below:

EKSO' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 5
Current: 3

During the past 12 years, the highest Piotroski F-Score of Ekso Bionics Holdings was 5. The lowest was 2. And the median was 3.


Ekso Bionics Holdings Piotroski F-Score Historical Data

The historical data trend for Ekso Bionics Holdings's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ekso Bionics Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 3.00 5.00 2.00 3.00

Ekso Bionics Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 2.00 2.00 2.00 3.00

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Ekso Bionics Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ekso Bionics Holdings Piotroski F-Score Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Ekso Bionics Holdings's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Ekso Bionics Holdings's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -4.389 + -4.23 + -3.365 + -3.214 = $-15.20 Mil.
Cash Flow from Operations was -4.214 + -2.903 + -3.353 + -1.584 = $-12.05 Mil.
Revenue was 4.122 + 4.703 + 4.607 + 4.847 = $18.28 Mil.
Gross Profit was 2 + 2.254 + 2.456 + 2.369 = $9.08 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(40.903 + 37.104 + 33.986 + 31.183 + 28.918) / 5 = $34.4188 Mil.
Total Assets at the begining of this year (Dec22) was $40.90 Mil.
Long-Term Debt & Capital Lease Obligation was $5.56 Mil.
Total Current Assets was $20.21 Mil.
Total Current Liabilities was $8.12 Mil.
Net Income was -4.62 + -2.978 + -4.304 + -3.178 = $-15.08 Mil.

Revenue was 2.567 + 3.465 + 3.329 + 3.551 = $12.91 Mil.
Gross Profit was 1.209 + 1.641 + 1.686 + 1.678 = $6.21 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(49.166 + 44.242 + 40.52 + 39.311 + 40.903) / 5 = $42.8284 Mil.
Total Assets at the begining of last year (Dec21) was $49.17 Mil.
Long-Term Debt & Capital Lease Obligation was $4.85 Mil.
Total Current Assets was $31.04 Mil.
Total Current Liabilities was $9.20 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Ekso Bionics Holdings's current Net Income (TTM) was -15.20. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Ekso Bionics Holdings's current Cash Flow from Operations (TTM) was -12.05. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-15.198/40.903
=-0.37156199

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-15.08/49.166
=-0.30671602

Ekso Bionics Holdings's return on assets of this year was -0.37156199. Ekso Bionics Holdings's return on assets of last year was -0.30671602. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Ekso Bionics Holdings's current Net Income (TTM) was -15.20. Ekso Bionics Holdings's current Cash Flow from Operations (TTM) was -12.05. ==> -12.05 > -15.20 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=5.555/34.4188
=0.16139435

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=4.854/42.8284
=0.11333601

Ekso Bionics Holdings's gearing of this year was 0.16139435. Ekso Bionics Holdings's gearing of last year was 0.11333601. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=20.208/8.117
=2.48958975

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=31.037/9.201
=3.3732203

Ekso Bionics Holdings's current ratio of this year was 2.48958975. Ekso Bionics Holdings's current ratio of last year was 3.3732203. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Ekso Bionics Holdings's number of shares in issue this year was 14.452. Ekso Bionics Holdings's number of shares in issue last year was 13.16. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=9.079/18.279
=0.49669019

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=6.214/12.912
=0.48125774

Ekso Bionics Holdings's gross margin of this year was 0.49669019. Ekso Bionics Holdings's gross margin of last year was 0.48125774. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=18.279/40.903
=0.44688654

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=12.912/49.166
=0.26262051

Ekso Bionics Holdings's asset turnover of this year was 0.44688654. Ekso Bionics Holdings's asset turnover of last year was 0.26262051. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+1+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Ekso Bionics Holdings has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Ekso Bionics Holdings  (NAS:EKSO) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Ekso Bionics Holdings Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Ekso Bionics Holdings's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Ekso Bionics Holdings (Ekso Bionics Holdings) Business Description

Traded in Other Exchanges
Address
101 Glacier Point, Suite A, San Rafael, CA, USA, 94901
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are EksoHealth and EksoWorks. All of the company's operations are held in the United States. The EksoHealth segment which derives majority revenue designs, engineers, manufactures and sells exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The regions company operates in are the Americas, EMEA, and APAC.
Executives
Jerome Wong officer: Interim CFO C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Scott G. Davis officer: President & COO C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Steven Sherman director
Jason C Jones officer: VP of Product Development EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
John Glenn officer: Chief Financial Officer 7900 HOPYARD ROAD, APT 210, PLEASANTON CA 94577
Lathan Corinna director 140 KENDRICK STREET, NEEDHAM MA 02494
William R Shaw officer: See Remarks 1414 HARBOUR WAY SOUTH, SUITE 1201, C/O EKSO BIONICS HOLDINGS, INC., RICHMOND CA 94804
Rhonda A. Wallen director C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Mary Ann Cloyd director 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Combest Development (hong Kong) Ltd 10 percent owner ROOM 2210, CC WU BUILDING 302, HENNESSY ROAD, WAN CHAI, HONG KONG K3 999077
Jack Peurach director, officer: Chief Executive Officer 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Thomas A Schreck director 10240 BUBB RD, CUPERTINO CA 95014
Puissance Capital Management Lp 10 percent owner 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Christian Babini officer: VP of Sales, Americas C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1, RICHMOND CA 94804
Puissance Cross-border Opportunities Ii Llc 10 percent owner C/O PUISSANCE CAPITAL FUND (GP) LLC, 950 THIRD AVENUE, NEW YORK NY 10022